| Assessment Status | Rapid review complete |
| HTA ID | 21022 |
| Drug | Enzalutamide |
| Brand | Xtandi® |
| Indication | For the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy. |
| Assessment Process | |
| Rapid review commissioned | 09/06/2021 |
| Rapid review completed | 07/07/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of enzalutamide in combination with androgen deprivation therapy compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
